Company intelligence / Profile preview

Gelesis

Boston, Massachusetts, United Statesgelesis.com ↗

Ownership: Private
Development stage: Commercial

Overview

Developed Plenity (Gelesis100), an FDA-cleared weight management aid for adults with BMI 25-40 kg/m², showing that responders lost on average 10% of their weight (22 pounds) and 3.5 inches from their waists within 6 months in pivotal study

Therapeutic areas: GastroenterologyEndocrinologyMetabolic Disorders
Modalities: Hydrogel technology (medical device)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Plenity

Commercial

Indications: Weight management

Partnerships

China Medical Systems Holdings Limited (CMS)

Beyond the preview

Go deeper on Gelesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gelesis.

Explore the full profile